Čájehuvvojit 1 - 4 oktiibuot 4 bohtosis ohcui Lisa L Ross', ohcanáigi: 0,03s Aiddostahte ozu
  1. 1
    HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects

    HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57... Dahkki Catherine Butkus Small, David A. Margolis, Mark S. Shaefer, Lisa L. Ross

    Almmustuhtton 2017-04-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

    Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. Dahkki David A Wohl, Laveeza Bhatti, Catherine B Small, Howard Edelstein, Henry H Zhao, David A Margolis, Edwin DeJesus, Winkler G Weinberg, Lisa L Ross, Mark S Shaefer

    Almmustuhtton 2014-01-01
    Viečča ollesdeavstta
    Artihkal
  3. 3
    HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.

    HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing. Dahkki Lisa L Ross, Joseph Horton, Samiul Hasan, James R Brown, Daniel Murphy, Edwin DeJesus, Martin Potter, Anthony LaMarca, Ivan Melendez-Rivera, Douglas Ward, Jonathon Uy, Mark S Shaefer

    Almmustuhtton 2014-01-01
    Viečča ollesdeavstta
    Artihkal
  4. 4
    Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.

    Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro... Dahkki Lisa L Ross, A Sarah Walker, Yu Lou, Allan R Tenorio, Diana M Gibb, Julia Double, Charles Gilks, Cynthia C McCoig, Paula Munderi, Godfrey Musoro, Cissy M Kityo, Heiner Grosskurth, James Hakim, Peter N Mugyenyi, Amy Cutrell, Teodora Perger, Mark S Shaefer

    Almmustuhtton 2019-01-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: